Movatterモバイル変換


[0]ホーム

URL:


DE2134179A1 - Prepns contg several bifidobacterium species - for normalizing intestinal flora - Google Patents

Prepns contg several bifidobacterium species - for normalizing intestinal flora

Info

Publication number
DE2134179A1
DE2134179A1DE2134179ADE2134179ADE2134179A1DE 2134179 A1DE2134179 A1DE 2134179A1DE 2134179 ADE2134179 ADE 2134179ADE 2134179 ADE2134179 ADE 2134179ADE 2134179 A1DE2134179 A1DE 2134179A1
Authority
DE
Germany
Prior art keywords
germs
flora
intestinal
intestinal flora
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE2134179A
Other languages
German (de)
Inventor
Rolf Dr Schuler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IndividualfiledCriticalIndividual
Priority to DE2134179ApriorityCriticalpatent/DE2134179A1/en
Publication of DE2134179A1publicationCriticalpatent/DE2134179A1/en
Pendinglegal-statusCriticalCurrent

Links

Classifications

Landscapes

Abstract

Prepn. for the substitution of defective intestinal flora or for maintaining normal flora conditions, contg. several species of the genus Bifidobacterium as a mixt. For treating dysbiotic intestinal flora conditions, e.g. after antibiotic treatment. The prepn. can replace all the species (often up to 7) of Bifidobacteria which were originally present in the intestinal tract. The mixt. may be in fresh form or in carefully dried. The prepn. pref. also contains other essential intestinal germs, and an optimal nutrient substrate, pref. milk or whey with added growth activators, esp. yeast extract or yeast autolysate. The Bifidobacteria are pref. cultured as pure cultures and then mixed.

Description

Translated fromGerman

"Bifidobakterien enthaltendes Präparat und Verfahren zur Herstellungdesselben" Die Erfindung bezieht sich auf ein Bifidobakterien enthaltendes Präparatzur Substitution gestörter Darmfloren bzw. zur Aufrechterhaltung normaler Floraverhältnissesowie auf ein Verfahren sur Herstellung dieses Präparates."Preparation containing bifidobacteria and process for productionthe same "The invention relates to a preparation containing bifidobacteriato replace disturbed intestinal flora or to maintain normal flora conditionsas well as a process for the production of this preparation.

Es ist bekannt, daß unter der Vielzahl von Mikroorganismen, die denmenschlichen Darmkanal besiedeln, bestimmte Bakteriengruppen, zum Beispiel Colikeimeoder verschiedene Arten von Laktobasillen von besonderer Bedeutung sind.It is known that among the multitude of microorganisms which thecolonize the human intestinal tract, certain groups of bacteria, for example coli germsor different types of lactobasils are of particular importance.

In neuerer Zeit konnte festgestellt werden, daß der menschliche Darmkanalzu etwa 40 % von Keimen der Bifidusgruppe und ru weiteren 40 % von keimen der Bacteroidesgruppebesiedelt ist. Dagegen beträgt der Anteil der aeroben Laktobasillen nur X nl 5 %der Gesamtkeimsahl und die coliformen Keime dürfen im Normalfall eine Gesamtkeimzahlvon rund 1 % nicht übersteigen. Die prozentualen Restanteile entfallen auf zahlreicheandere Keimgruppen (Catenabakterien, Corynebakterion, Streptokokken u.a.), überderen physiologische Bedeutung bis Jetzt nichts bekannt ist.More recently it has been found that the human intestinal canalabout 40% of germs of the bifidus group and another 40% of germs of the Bacteroides groupis populated. In contrast, the proportion of aerobic lactobasils is only X nl 5%the total number of germs and the coliforms may normally have a total number of germsof around 1%. The remaining percentages are attributable to numerousother groups of germs (catenabacteria, corynebacteria, streptococci, etc.), overwhose physiological significance is not yet known.

Alle bisher aufgefundenen Darmkeime, einschließlich der Colibakterien,sind als potentiell pathogene Keime anzusehen, das heißt, sie kannen sowohl im Dannselbst, sofern eine gestörte Darmflora vorliegt, als Krankheitserregerwirksam werden, sie können Jedoch auch außerhalb des Darmes auf Schleihhäuten oderin Wunden, Entzündungen oder Eiterungen hervorrufen.All intestinal germs found so far, including coli bacteria,are to be regarded as potentially pathogenic germs, that is, they can both in the theneven if a disturbed oneIntestinal flora is present as a pathogenThey can be effective, however, also outside of the intestine on coarse membranes orcause inflammation or suppuration in wounds.

Die einzige, bisher bekannte Ausnahme in dieser Beziehung bilden dieKeime der Bifidusgruppe. Diese sind von allen bisher im Darm aufgefundenen Mikroorganismendie einzigen wirklich apathogenen Keime. Vermutlich ist die Aufrechterhaltung normalerFloraverhältnisse in erster Linie dieser Kelingruppe zuzuschreiben. So ist es bekannt,daß mit Muttermilch ernährte Säuglinge eine praktisch reine Bifidusflora in ihremDarm beherbergen und daß das Gedeihen dieser Säuglinge in einem direkten Zusammenhangmit dieser Bifidusflora steht.The only known exception in this respect are theGerms of the bifidus group. These are from all microorganisms previously found in the intestinethe only really non-pathogenic germs. Presumably maintenance is more normalFlora conditions can be attributed primarily to this kelo group. So it is knownthat breast-fed infants have practically pure bifidus flora in theirsGut accommodate and that the thriving of these infants is directly relatedwith this bifidus flora.

Bifidobakterien richten durch ihr starkes Säuerungsvermögen in denoberen Darmabschnitten eine "Säureschranke" auf, welche es den in den tieferen Darmabschnittensiedelnden Fäulniserregern verwehrt, in höhere Darmabschnitte aufzusteigen, wo siepathogen wirksam werden könnten.Bifidobacteria direct due to their strong acidity in theupper intestinal sections create an "acid barrier", which is present in the deeper intestinal sectionscolonizing putrefactive pathogens are prevented from ascending into higher intestinal sections, where theycould be pathogenic.

Bifidobakterien bilden eine antibiotisch wirksame Substanz, die sichgegen gramnegative und auch gegen gewisse grampositive Keime richtet.Bifidobacteria form a substance that has an antibiotic effectdirected against gram-negative and also against certain gram-positive germs.

Es ist schon versucht worden, die gestörten Darmflorcn (z.B.Attempts have already been made to remove the disturbed intestinal flora (e.g.

nach antibiotiabher Behandlung) dadurch wieder zu normalisieren, daßman lebende Bifiduskeime in entsprechend großer Menge suführte, in der Hoffnung,daß eine Ansiedelung dieser Keime im Darmtrakt möglich sei. Es hat sich Jedoch erwiesen,daß diese Bifiduskeime war als sogenaante passagere Keime den Darmtrakt durchwandernund in der Fäkalflora wiedersufinden sind, daß aber eine echte Ansiedelung dieserKeime nur in sehr wenigen Fällen gelingt. In der Regel verschwanden auch die inder Fähalflora nachweisbaren zugeführten Biiiduskeime bald nach dem Absetzen derentsprechenden Präparate.after antibiotic treatment) to normalize again thatliving bifidus germs were fed in correspondingly large quantities, in the hope thatthat a settlement of these germs in the intestinal tract is possible. However, it has been shownthat these bifidus germs were passing through the intestinal tract as so-called transient germsand are found again in the faecal flora, but that there is a real settlement of theseGerms only succeed in very few cases. Usually the inthe fähalflora detectable supplied Biiidus germs soon after the weaningcorresponding preparations.

Aufgabe der Erfindung irt es, ein Präparat zu schaffen, welches zurBehandlung sogenannter dysbiotischer Darmflorengeeignet ist undanhaltende Ansiedelung bzw. Neuanziedelung von humanen Btfidusarten im Darmtraktbewirkt.The object of the invention irt it to create a preparation which forTreatment of so-called dysbiotic intestinal florais suitable andsustained settlement or new settlement of human Btfidus species in the intestinal tractcauses.

Es wurde festgestellt, daß die Bifidusflora Jeder Person sehr heterogenzusammengesetzt ist. Von den derzeit bekannten, rund 15 verschiedenen Arten vonBifidobakterien beherbergt Jeder Mensch in seinem Intestinaltrakt mehrere, oft biszu 7 verschiedene Arten. Es hat sich als praktisch unmöglich erwiesen, eine andereBifidusart als die bereits im Darmkanal vorhandenen Arten, anzusiedeln. Es ist Jedochdurchaus eine Ansiedelung einer oder mehrerer Arten möglich, die bei einer bestimmtenPerson bereits vorhanden sind, wenn auch (etwa durch antibiotische Schädigung) nurnoch in sehr geringer und für die Aufrechterhaltung normaler Floraverhältnisse ungenügenderAnzahl.It was found that the bifidus flora of every person is very heterogeneousis composed. Of the currently known, around 15 different types ofEvery person harbors several, often up to, bifidobacteria in their intestinal tractto 7 different types. It has proven practically impossible any otherBifidus species than the species already present in the intestinal canal. However, it isA settlement of one or more species is quite possible, with a certainPerson already exist, even if only (e.g. due to antibiotic damage)still very little and inadequate for the maintenance of normal flora conditionsNumber.

Die bisher zur Behandlung von florabedingten Darmstörungen angewandtenPräparate enthielten lediglich eine einzig.The previously used for the treatment of flora-related intestinal disordersPreparations contained only one.

Bifidusart. Es ist daher erklärlich, daß anhaltende therapeutischeErfolge mit solchen Präparaten nur bei Personen erreicht werden konnten, die ebendiese eine Art in ihrem Darm beherbergten.Bifidus species. It is therefore understandable that persistent therapeuticSuccesses with such preparations could only be achieved with people whoharbored this one species in their intestines.

Die vorstehend erläuterte Aufgabe wird dadurch gelöst, daß das erfindungsgemäßePräparat mehrere Arten der Gattung Bifidobakterien als Mischung enthält.The object explained above is achieved in that the inventivePreparation containing several species of the genus Bifidobacteria as a mixture.

Die Mischung kann in frischer Form verwendet werden, sie kann jedochauch schonend getroclnet sein.The mixture can be used fresh, but it canalso be gently dried.

Weiterhin kann die Mischung zusätzliche essentielle Keime der Darmflorasowie ein optimales Nährsubstrat enthalten.Furthermore, the mixture can contain additional essential germs of the intestinal floraas well as an optimal nutrient substrate.

Als NJhrsubstrat eignet sich Milch oder Molke, die mit einem Zusatzvon Wachstumsaktivatoren versehen sein kann. Diese Wachstumsaktivatoren können Hefeextrakteoder Hefeautolysate sein.Milk or whey with an additive is suitable as a nutrient substratecan be provided by growth activators. These growth activators can be yeast extractsor yeast autolysates.

Das erfindungsgemäße Präparat kann dadurch hergestellt werden, daßmehrere Arten der Gattung Bitidobakterien als Reinkulturen für sich kultiviert unddann miteinander vermischt werden.The preparation according to the invention can be produced in thatseveral species of the genus Bitidobacteria cultivated as pure cultures for themselves andthen mixed together.

Die Mischung kann schonend getrocknet werden. Es können der Mischungauch andere exxentielle Keime der Darmflora ebenso wie ein optimales Nährsubstratzugesetzt werden.The mixture can be gently dried. It can mixalso other exxential germs of the intestinal flora as well as an optimal nutrient substratecan be added.

Die Keime der Darmflore können vor der Vermischung mit den verschiedenenStämmen der 3ifidobakterien in dem Nährsubstrat selbst kultiviert werden. Als Nhhrsubstratkann Milch oder Molke verwendet werden, der Wachstumsaktivatoren zugesetzt seinkönnen. Als Wachstumsaktivatoren eignen sich z.B, Hefeextrakte oder Hefeautolysate.The germs of the intestinal flora can prevent mixing with the variousStrains of the 3ifidobacteria are cultivated in the nutrient substrate itself. As a sewing substratemilk or whey can be used to which growth activators have been addedcan. Examples of suitable growth activators are yeast extracts or yeast autolysates.

Die Erfindung wird nachfolgend anhand von zwei Beispielen erläutert:Beispiel 11 Reinkulturen von Bifidobakterien, die t.B.The invention is explained below using two examples:Example 11 Pure cultures of bifidobacteria produced by t.B.

nach dem deutschen Patent 19 46 661 gewonnen wurden, werden in Milchmit einem Zusatz von Hefeextrakt oder Hefeautolysat weitergesüchtet, durch dieseWeiterzüchtung aui ein beliebig großes Volumen vermehrt, sodann miteinander im gleichenVerhältnis, bezogen auf die Keimzahlen der Kulturen, vermischt. Dieses Gemisch eignetsich in frischer oder schonend getrockneter Form zur Behandlung gestörter Darmfloren. according to the German patent 19 46 661 are obtained in milkwith the addition of yeast extract or yeast autolysate are further addicted by thisFurther breeding increased to an arbitrarily large volume, then with one another in the same wayRatio, based on the number of germs in the cultures, mixed. This mixture is suitablein fresh or gently dried form for the treatment of disturbed intestinal flora.

Beispiel 2) Reinkulturen von Bifidobakterien werden miteinander vermischtwie nach Beispiel 1. Nach der Vermischung dieser Kulturen miteinander kann dieseMischkultur entweder allein oder in Verbindung mit anderen Milchsäurebildern surHerstellung von Milcherzeugnissen verwendet werden, die dann den gleichen Zweckendienen können wie das nach Beispiel 1 gewonnene Präparat.Example 2) Pure cultures of bifidobacteria are mixed with one anotheras in Example 1. After these cultures have been mixed with one another, this canMixed culture either alone or in conjunction with other lactic acid images surManufacture of dairy products are used, which then serve the same purposescan serve like the preparation obtained according to Example 1.

Das im Rahmen der Erfindung vorgesehene gleichzeitige Verabreichenvon Bifidobakterien und einem für diese Keime optimalen Nährsubstrat schafft günstigeLebensbedingungen im Darmkanal, die für die erfolgreiche Ansiedelung der Bifidobakteriensehr förderlich ist.The simultaneous administration provided within the scope of the inventionof bifidobacteria and an optimal nutrient substrate for these germs creates favorableLiving conditions in the intestinal tract that are necessary for the successful settlement of the bifidobacteriais very beneficial.

P a t e n t a n s p r ü c h e P a t e n t a n s p r ü c h e

Claims (14)

Translated fromGerman
P a t e n t a n s p r ü c h e 1.) Bifidobakterien enthaltendes Präparatzur Substitution gestörter Darmfloren bzw. zur Aufrechterhaltung normaler Floraverhältnisse'dadurch gekennzeichnet, daß es mehrere Arten der Gattung Bifidobakterium als Mischungenthält.P a t e n t a n s p r ü c h e 1.) Preparation containing bifidobacteriato replace disturbed intestinal flora or to maintain normal flora conditions'characterized in that there are several species of the genus Bifidobacterium as a mixturecontains.2.) Präparat nach Anspruch 1, dadurch gekennzeichnet, daß es die Mischungin frischer Form enthält.2.) Preparation according to claim 1, characterized in that it is the mixturecontains in fresh form.3.) Präparat nach Anspruch 1, dadurch gekennzeichnet, daß es die Mischungin schonend getrockneter Form enthält.3.) Preparation according to claim 1, characterized in that it is the mixturecontains in gently dried form.4.) Präparat nach Anspruch 1, dadurch gekennzeichnet, daß es nebender Mischung andere essentielle Keime der Damflora enthält.4.) Preparation according to claim 1, characterized in that it is next tothe mixture contains other essential germs of the dam flora.5.) Präparat nach Anspruch 4, dadurch gekennzeichnet, daß es ein optionalesNährsubstrat enthält.5.) Preparation according to claim 4, characterized in that it is an optionalContains nutrient substrate.6.) Präparat nach Anspruch 5, dadurch gekennzeichnet, daß als NährsubstratMilch oder Mo3Fke mit einem Zusats von Wachstumsaktivatoren vorgesehen ist.6.) Preparation according to claim 5, characterized in that as a nutrient substrateMilk or Mo3Fke with an addition of growth activators is provided.7.) parat nach Anspruch 6, dadurch gekennzeichnet, daß als WachstumsaktivatorenHefeextrakte oder Hefeautolysate vorgesehen sind.7.) ready according to claim 6, characterized in that as growth activatorsYeast extracts or yeast autolysates are provided.8.) Verfahren zur Herstellung des Präparates nach einem oder mehrerender vorhergehenden Anspruche, dadurch gekennseichnet, daß mehrere Arten der GattungBifidobakterien als Reinkulturen kultiviert und dann miteinander vermischt werden.8.) Process for the preparation of the preparation according to one or moreof the preceding claims, characterized in that several species of the genusBifidobacteria are cultivated as pure cultures and then mixed with one another.9.) Verfahren nach Anspruch 8, dadurch gekennzeichnet, daß die Mischungschonend getrocknet wird.9.) The method according to claim 8, characterized in that the mixtureis gently dried.10.) Verfahren nach Anspruch 8, dadurch gekennzeichnet, daß der Mischungandere essentielle Keime der Darmflora sugesetzt werden.10.) The method according to claim 8, characterized in that the mixtureother essential germs of the intestinal flora are put in place.11.) Verfahren nach Anspruch 8, dadurch gekennzeichnet, d¢ der Mischungein optimales Nährsubstrat zugesetzt wird.11.) The method according to claim 8, characterized in that d ¢ the mixturean optimal nutrient substrate is added.12.) Verfahren nach den Ansprüche 10 und 11, dadurch gekennseichnet,daß die Keime der Darmflora vor der Beimischung in dem NUhrsubstrat kultiviert werden.12.) Method according to claims 10 and 11, characterized in thatthat the germs of the intestinal flora are cultivated in the nutrient substrate before admixture.13.) Verfahren nach Anspruch 11, dadurch gekennzeichnet, daß als NährsubstratMilch oder Molke mit einem Zusatz ton Wachatumsaktivatoren verwendet wird.13.) The method according to claim 11, characterized in that as a nutrient substrateMilk or whey with an addition ton of wax-date activators is used.14.) Verfahren nach Anspruch 13, dadurch gekennzeichnet, daß als WachstumsaktivatorenHefeextrakte oder Hefeautolysate verwendet werden.14.) The method according to claim 13, characterized in that as growth activatorsYeast extracts or yeast autolysates can be used.
DE2134179A1971-07-091971-07-09Prepns contg several bifidobacterium species - for normalizing intestinal floraPendingDE2134179A1 (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
DE2134179ADE2134179A1 (en)1971-07-091971-07-09Prepns contg several bifidobacterium species - for normalizing intestinal flora

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
DE2134179ADE2134179A1 (en)1971-07-091971-07-09Prepns contg several bifidobacterium species - for normalizing intestinal flora

Publications (1)

Publication NumberPublication Date
DE2134179A1true DE2134179A1 (en)1973-01-25

Family

ID=5813114

Family Applications (1)

Application NumberTitlePriority DateFiling Date
DE2134179APendingDE2134179A1 (en)1971-07-091971-07-09Prepns contg several bifidobacterium species - for normalizing intestinal flora

Country Status (1)

CountryLink
DE (1)DE2134179A1 (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
DE2813733A1 (en)*1977-03-311978-10-12Yakult Honsha Kk PROCESS FOR THE MANUFACTURING OF FOOD AND BEVERAGES CONTAINING BIFIDOBACTERIA
US4335107A (en)*1978-06-051982-06-15Snoeyenbos Glenn HMixture to protect poultry from salmonella
DE3125797A1 (en)*1981-06-301983-01-13Rudolf Dr. SchulerDietetic agent
FR2560046A1 (en)*1984-02-241985-08-30Schuler RudolfDietetic product contg. bifidobacterium suis or infantis
EP0181170A3 (en)*1984-11-051988-03-16Kabushiki Kaisya Advance Kaihatsu KenkyujoHypocholesterolemically active products
WO1990001335A1 (en)*1988-08-021990-02-22Borody Thomas JTreatment of gastro-intestinal disorders
EP0482530A3 (en)*1990-10-251993-03-31Karl Heinz HoelzelComposition for the regulation of intestinal flora
US5443826A (en)*1988-08-021995-08-22Borody; Thomas J.Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
US9320763B2 (en)2000-07-252016-04-26Thomas Julius BorodyProbiotic recolonisation therapy
US9649343B2 (en)2011-03-092017-05-16National Institutes of Health (NIH); U.S. Department of Health and Human Services (DHHS); The United States of America, NIH Division of Extramural Inventions and Tehnology Resources (DEITR)Compositions and methods for transplantation of colon microbiota
US9901603B2 (en)2015-05-142018-02-27Crestovo Holdings LlcCompositions for fecal floral transplantation and methods for making and using them and device for delivering them
US9962413B2 (en)2010-08-042018-05-08Crestovo Holdings LlcCompositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10092601B2 (en)2016-10-112018-10-09Crestovo Holdings LlcCompositions and methods for treating multiple sclerosis and related disorders
US10195235B2 (en)2016-08-032019-02-05Crestovo Holdings LlcMethods for treating ulcerative colitis
US11026978B2 (en)2016-10-112021-06-08Finch Therapeutics Holdings LlcCompositions and methods for treating multiple sclerosis and related disorders
US11040073B2 (en)2017-04-052021-06-22Finch Therapeutics Holdings LlcCompositions and methods for treating diverticulitis and related disorders
US11166990B2 (en)2018-07-132021-11-09Finch Therapeutics Holdings LlcMethods and compositions for treating ulcerative colitis
US11202808B2 (en)2015-05-222021-12-21Arizona Board Of Regents On Behalf Of Arizona State UniversityMethods for treating autism spectrum disorder and associated symptoms
US11213549B2 (en)2016-10-112022-01-04Finch Therapeutics Holdings LlcCompositions and method for treating primary sclerosing cholangitis and related disorders
US11357801B2 (en)2016-06-152022-06-14Arizona Board Of Regents On Behalf Of Arizona State UniversityMethods for treating autism spectrum disorder and associated symptoms
US11433102B2 (en)2017-04-052022-09-06Finch Therapeutics Holdings LlcCompositions and methods for treating Parkinson's disease (PD) and related disorders
US11542560B2 (en)2012-05-252023-01-03Board of Regents on Behalf of Arizona State UniversityMicrobiome markers and therapies for autism spectrum disorders
US11819523B2 (en)2016-07-012023-11-21Regents Of The University Of MinnesotaCompositions and methods for C. difficile treatment
US11865145B2 (en)2017-08-072024-01-09Finch Therapeutics Holdings LlcCompositions and methods for maintaining and restoring a healthy gut barrier
US11890306B2 (en)2017-05-262024-02-06Finch Therapeutics Holdings LlcLyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
US11911419B2 (en)2018-09-272024-02-27Finch Therapeutics Holdings LlcCompositions and methods for treating epilepsy and related disorders
US12290538B2 (en)2019-07-192025-05-06Finch Therapeutics Holdings LlcMethods and products for treatment of gastrointestinal disorders

Cited By (81)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
DE2813733A1 (en)*1977-03-311978-10-12Yakult Honsha Kk PROCESS FOR THE MANUFACTURING OF FOOD AND BEVERAGES CONTAINING BIFIDOBACTERIA
US4335107A (en)*1978-06-051982-06-15Snoeyenbos Glenn HMixture to protect poultry from salmonella
DE3125797A1 (en)*1981-06-301983-01-13Rudolf Dr. SchulerDietetic agent
FR2560046A1 (en)*1984-02-241985-08-30Schuler RudolfDietetic product contg. bifidobacterium suis or infantis
EP0181170A3 (en)*1984-11-051988-03-16Kabushiki Kaisya Advance Kaihatsu KenkyujoHypocholesterolemically active products
WO1990001335A1 (en)*1988-08-021990-02-22Borody Thomas JTreatment of gastro-intestinal disorders
US5443826A (en)*1988-08-021995-08-22Borody; Thomas J.Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
US6645530B1 (en)1988-08-022003-11-11Gastro Services Pty LimitedTreatment of gastro-intestinal disorders
EP0482530A3 (en)*1990-10-251993-03-31Karl Heinz HoelzelComposition for the regulation of intestinal flora
US9623056B2 (en)2000-07-202017-04-18Crestovo LlcProbiotic recolonisation therapy
US9572841B2 (en)2000-07-252017-02-21Crestovo LlcProbiotic recolonisation therapy
US9682108B2 (en)2000-07-252017-06-20Crestovo LlcProbiotic recolonisation therapy
US10369175B2 (en)2000-07-252019-08-06Crestovo Holdings LlcProbiotic recolonisation therapy
US9572842B2 (en)2000-07-252017-02-21Crestovo LlcProbiotic recolonisation therapy
US9610308B2 (en)2000-07-252017-04-04Crestovo LlcProbiotic recolonisation therapy
US9408872B2 (en)2000-07-252016-08-09Crestovo LlcProbiotic recolonisation therapy
US10772919B2 (en)2000-07-252020-09-15Crestovo Holdings LlcProbiotic recolonisation therapy
US9468658B2 (en)2000-07-252016-10-18Crestovo LlcProbiotic recolonisation therapy
US9737574B2 (en)2000-07-252017-08-22Crestovo LlcProbiotic recolonisation therapy
US9789140B2 (en)2000-07-252017-10-17Crestovo Holdings LlcProbiotic recolonisation therapy
US9867858B2 (en)2000-07-252018-01-16Crestovo Holdings LlcProbiotic recolonisation therapy
US9320763B2 (en)2000-07-252016-04-26Thomas Julius BorodyProbiotic recolonisation therapy
US9901604B2 (en)2000-07-252018-02-27Crestovo Holdings LlcProbiotic recolonisation therapy
US9962414B2 (en)2000-07-252018-05-08Crestovo Holdings LlcProbiotic recolonisation therapy
US10617724B2 (en)2010-08-042020-04-14Crestovo Holdings LlcCompositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11065284B2 (en)2010-08-042021-07-20Finch Therapeutics Holdings LlcCompositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10022406B2 (en)2010-08-042018-07-17Crestovo Holdings LlcCompositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11491193B2 (en)2010-08-042022-11-08Finch Therapeutics Holdings LlcCompositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10064899B1 (en)2010-08-042018-09-04Crestovo Holdings LlcCompositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11173183B2 (en)2010-08-042021-11-16Finch Therapeutics Holdings LlcCompositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11504403B2 (en)2010-08-042022-11-22Finch Therapeutics Holdings LlcCompositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11129859B2 (en)2010-08-042021-09-28Finch Therapeutics Holdings LlcCompositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10278997B2 (en)2010-08-042019-05-07Crestovo Holdings LlcCompositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11541080B2 (en)2010-08-042023-01-03Finch Therapeutics Holdings LlcCompositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11103541B2 (en)2010-08-042021-08-31Finch Therapeutics Holdings LlcCompositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10328107B2 (en)2010-08-042019-06-25Crestovo Holdings LlcCompositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US9962413B2 (en)2010-08-042018-05-08Crestovo Holdings LlcCompositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10463702B2 (en)2010-08-042019-11-05Crestovo Holdings LlcCompositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11890308B2 (en)2010-08-042024-02-06Finch Therapeutics Holdings LlcCompositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10610551B2 (en)2010-08-042020-04-07Crestovo Holdings, Inc.Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11207356B2 (en)2010-08-042021-12-28Finch Therapeutics Holdings LlcCompositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10675309B2 (en)2010-08-042020-06-09Crestovo Holdings LlcCompositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11850269B2 (en)2010-08-042023-12-26Finch Therapeutics Holdings LlcCompositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11890307B2 (en)2010-08-042024-02-06Finch Therapeutics Holdings LlcCompositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10849937B2 (en)2010-08-042020-12-01Crestovo Holdings LlcCompositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10857188B2 (en)2010-08-042020-12-08Crestovo Holdings LlcCompositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10987385B2 (en)2010-08-042021-04-27Finch Therapeutics Holdings LlcCompositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US9649343B2 (en)2011-03-092017-05-16National Institutes of Health (NIH); U.S. Department of Health and Human Services (DHHS); The United States of America, NIH Division of Extramural Inventions and Tehnology Resources (DEITR)Compositions and methods for transplantation of colon microbiota
US11801269B2 (en)2011-03-092023-10-31Regents Of The University Of MinnesotaCompositions and methods for transplantation of colon microbiota
US9968638B2 (en)2011-03-092018-05-15Regents Of The University Of MinnesotaCompositions and methods for transplantation of colon microbiota
US10286012B2 (en)2011-03-092019-05-14Regents Of The University Of MinnesotaCompositions and methods for transplantation of colon microbiota
US10286011B2 (en)2011-03-092019-05-14Regents Of The University Of MinnesotaCompositions and methods for transplantation of colon microbiota
US10251914B2 (en)2011-03-092019-04-09Regents Of The University Of MinnesotaCompositions and methods for transplantation of colon microbiota
US12295974B2 (en)2011-03-092025-05-13Regents Of The University Of MinnesotaCompositions and methods for transplantation of colon microbiota
US10028980B2 (en)2011-03-092018-07-24Regents Of The University Of MinnesotaCompositions and methods for transplantation of colon microbiota
US11542560B2 (en)2012-05-252023-01-03Board of Regents on Behalf of Arizona State UniversityMicrobiome markers and therapies for autism spectrum disorders
US12084727B2 (en)2012-05-252024-09-10Arizona Board Of Regents On Behalf Of Arizona State UniversityMicrobiome markers and therapies for autism spectrum disorders
US9901603B2 (en)2015-05-142018-02-27Crestovo Holdings LlcCompositions for fecal floral transplantation and methods for making and using them and device for delivering them
US11123377B2 (en)2015-05-142021-09-21Finch Therapeutics Holdings LlcCompositions for fecal floral transplantation and methods for making and using them and device for delivering them
US10821138B2 (en)2015-05-142020-11-03Crestovo Holdings LlcCompositions for fecal floral transplantation and methods for making and using them and device for delivering them
US12161678B2 (en)2015-05-142024-12-10Finch Therapeutics Holdings LlcCompositions for fecal floral transplantation and methods for making and using them and device for delivering them
US11202808B2 (en)2015-05-222021-12-21Arizona Board Of Regents On Behalf Of Arizona State UniversityMethods for treating autism spectrum disorder and associated symptoms
US11357801B2 (en)2016-06-152022-06-14Arizona Board Of Regents On Behalf Of Arizona State UniversityMethods for treating autism spectrum disorder and associated symptoms
US12186349B2 (en)2016-07-012025-01-07Regents Of The University Of MinnesotaCompositions and methods for C. difficile treatment
US11819523B2 (en)2016-07-012023-11-21Regents Of The University Of MinnesotaCompositions and methods for C. difficile treatment
US10561690B2 (en)2016-08-032020-02-18Crestovo Holdings LlcMethods for treating ulcerative colitis
US11071759B2 (en)2016-08-032021-07-27Finch Therapeutics Holdings LlcMethods for treating ulcerative colitis
US12390496B2 (en)2016-08-032025-08-19Finch Therapeutics Holdings LlcMethods for treating ulcerative colitis
US10195235B2 (en)2016-08-032019-02-05Crestovo Holdings LlcMethods for treating ulcerative colitis
US10092601B2 (en)2016-10-112018-10-09Crestovo Holdings LlcCompositions and methods for treating multiple sclerosis and related disorders
US11213549B2 (en)2016-10-112022-01-04Finch Therapeutics Holdings LlcCompositions and method for treating primary sclerosing cholangitis and related disorders
US11026978B2 (en)2016-10-112021-06-08Finch Therapeutics Holdings LlcCompositions and methods for treating multiple sclerosis and related disorders
US11529375B2 (en)2017-04-052022-12-20Finch Therapeutics Holdings LlcCompositions and methods for treating diverticulitis and related disorders
US11040073B2 (en)2017-04-052021-06-22Finch Therapeutics Holdings LlcCompositions and methods for treating diverticulitis and related disorders
US11433102B2 (en)2017-04-052022-09-06Finch Therapeutics Holdings LlcCompositions and methods for treating Parkinson's disease (PD) and related disorders
US11890306B2 (en)2017-05-262024-02-06Finch Therapeutics Holdings LlcLyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
US11865145B2 (en)2017-08-072024-01-09Finch Therapeutics Holdings LlcCompositions and methods for maintaining and restoring a healthy gut barrier
US12285447B2 (en)2018-07-132025-04-29Finch Therapeutics Holdings LlcMethods and compositions for treating ulcerative colitis
US11166990B2 (en)2018-07-132021-11-09Finch Therapeutics Holdings LlcMethods and compositions for treating ulcerative colitis
US11911419B2 (en)2018-09-272024-02-27Finch Therapeutics Holdings LlcCompositions and methods for treating epilepsy and related disorders
US12290538B2 (en)2019-07-192025-05-06Finch Therapeutics Holdings LlcMethods and products for treatment of gastrointestinal disorders

Similar Documents

PublicationPublication DateTitle
DE2134179A1 (en)Prepns contg several bifidobacterium species - for normalizing intestinal flora
DE69108846T2 (en) Whole foods made from hydrolyzed soluble fiber.
DE69227329T2 (en) Milk bacteria
CH638660A5 (en) METHOD FOR THE PRODUCTION OF FOODS AND BEVERAGES CONTAINING BIFIDOBACTERIES.
DE2250993C2 (en) Antibacterial agent
CH642517A5 (en) METHOD FOR THE PRODUCTION OF FOODS AND BEVERAGES CONTAINING BIFIDOBACTERIES.
CH665126A5 (en) DIETETARY AGENT FOR REDUCING THE UREA CONCENTRATION IN BODY LIQUIDS AND ITS PRODUCTION.
CH627348A5 (en) METHOD FOR THE PRODUCTION OF FERMENTED MILK CONTAINING VIVIDABLE BIFIDOBACTERIES AND USE OF THE MILK SO OBTAINED.
DE3120505C2 (en) Process for the production of solid sour milk products
DE69122186T2 (en) LACTOBACILLUS ACIDOPHILUS-F-133, PRODUCTION OF LACTIC ACID BACTERIA THEREOF AND METHOD FOR THE PRODUCTION THEREOF
DE69002024T2 (en) Bioactive lactoferrin derivatives.
CH650645A5 (en) DIET TABLE.
CH647945A5 (en)Lyophilised, enzymatically degraded sour milk product
DE2931082C2 (en)
DE1692313A1 (en) Process for making dairy products
DE1492779C3 (en) Process for the manufacture of sour milk products
EP0344786B1 (en)Inhibiting agent for clostridia
EP0184121B1 (en)Saccharose-containing, orally administered, foodstuffs, beverages, delicacies and pharmaceutical preparations
DE1019896B (en) Process for the production of milk products, such as sour milk or the like, with the addition of bacteria
DE2421066A1 (en)Bifido bacterial preparations - additionally contg. Lactobacillus casei var. rhamnosus
DE2106154A1 (en)Antibiotic - resistans streptococcus faecalis - for treatment and prophylaxis of digestive disturbances
DE3147311C2 (en)
EP0515721A1 (en)Method for producing vegetable foodstuff with low nitrate content
DE2057906A1 (en)Preacidulated milk for infants - without the risk of acidosis
DE859194C (en) Process for the cultivation of bacterial strains producing streptomycin

[8]ページ先頭

©2009-2025 Movatter.jp